ArticleFrontiers in immunology2026
Identification of a novel inflammatory mast cell subpopulation in triple-negative breast cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is associated with poor therapeutic outcomes, and increasing attention has been directed toward the tumor microenvironment (TME). Mast cells are an important component of the TME, yet their heterogeneity and functional roles in TNBC remain incompletely understood. Methods: Single-cell RNA sequencing data of TNBC were analyzed using the Seurat pipeline. Mast cells were extracted and re-clustered, and the subpopulations were characterized by functional enrichment, transcription factor, pseudotime, drug sensitivity, and cell-cell communication analyses. The role of the inflammatory subpopulation was further examined using an in silico virtual knockout approach and validated in a 4T1 subcutaneous tumor model in BALB/c mice. Results: Four transcriptionally distinct mast cell subpopulations were identified. Among them, the C4 subpopulation exhibited a pronounced inflammatory signature and was highly enriched in the NF-κB pathway. C4 was predicted to have lower sensitivity to several first-line chemotherapeutic agents and was associated with an unfavorable treatment response. Cell-cell communication analysis suggested that C4 may suppress CD8 Conclusions: We identified an inflammation-associated mast cell subpopulation (C4) that may contribute to TNBC progression, providing a potential target for future therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.